These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25084341)

  • 1. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
    Kolstoe SE; Jenvey MC; Purvis A; Light ME; Thompson D; Hughes P; Pepys MB; Wood SP
    Acta Crystallogr D Biol Crystallogr; 2014 Aug; 70(Pt 8):2232-40. PubMed ID: 25084341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
    Kolstoe SE; Ridha BH; Bellotti V; Wang N; Robinson CV; Crutch SJ; Keir G; Kukkastenvehmas R; Gallimore JR; Hutchinson WL; Hawkins PN; Wood SP; Rossor MN; Pepys MB
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7619-23. PubMed ID: 19372378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
    Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
    Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
    Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
    Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
    Sahota T; Berges A; Barton S; Cookson L; Zamuner S; Richards D
    CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
    Borthwick NJ; Lane T; Moyo N; Crook A; Shim JM; Baines I; Wee EG; Hawkins PN; Gillmore JD; Hanke T; Pepys MB
    PLoS One; 2018; 13(5):e0197299. PubMed ID: 29772028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug targets for amyloidosis.
    Kolstoe SE; Wood SP
    Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.
    Hohenester E; Hutchinson WL; Pepys MB; Wood SP
    J Mol Biol; 1997 Jun; 269(4):570-8. PubMed ID: 9217261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.
    Ashton AW; Boehm MK; Gallimore JR; Pepys MB; Perkins SJ
    J Mol Biol; 1997 Sep; 272(3):408-22. PubMed ID: 9325100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-assisted aggregation of proteins. Dimerization of serum amyloid P component by bivalent ligands.
    Ho JG; Kitov PI; Paszkiewicz E; Sadowska J; Bundle DR; Ng KK
    J Biol Chem; 2005 Sep; 280(36):31999-2008. PubMed ID: 16036920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
    Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
    Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoradiometric assay for human serum amyloid P component.
    Millar DJ; Hutchinson WL; Pepys MB
    J Immunol Methods; 2011 Aug; 371(1-2):18-24. PubMed ID: 21708157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component.
    Mikolajek H; Kolstoe SE; Pye VE; Mangione P; Pepys MB; Wood SP
    J Mol Recognit; 2011; 24(2):371-7. PubMed ID: 21360619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein heterodimerization through ligand-bridged multivalent pre-organization: enhancing ligand binding toward both protein targets.
    Liu J; Zhang Z; Tan X; Hol WG; Verlinde CL; Fan E
    J Am Chem Soc; 2005 Feb; 127(7):2044-5. PubMed ID: 15713072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of pentameric human serum amyloid P component.
    Emsley J; White HE; O'Hara BP; Oliva G; Srinivasan N; Tickle IJ; Blundell TL; Pepys MB; Wood SP
    Nature; 1994 Jan; 367(6461):338-45. PubMed ID: 8114934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose.
    Thompson D; Pepys MB; Tickle I; Wood S
    J Mol Biol; 2002 Jul; 320(5):1081-6. PubMed ID: 12126626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human serum amyloid P component is a single uncomplexed pentamer in whole serum.
    Hutchinson WL; Hohenester E; Pepys MB
    Mol Med; 2000 Jun; 6(6):482-93. PubMed ID: 10972085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.